Contact Us
Contact Us
Contact Us


Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements

13/03/2019Appendix 3BDownload
27/02/2019Appendix 4D & Half-Year Financial StatementsDownload
25/02/2019Principal Investigator appointed for BisantreneDownload
14/02/2019Appendix 3Y-Dr William GarnerDownload
12/02/2019Change in substantial holdingDownload
12/02/2019Change of Director's Interest Notice-Mr Chris NtoumenopoulosDownload
12/02/2019Change of Director's Interest Notice-Dr William GarnerDownload
12/02/2019Change of Director's Interest Notice-Mr Peter MolloyDownload
31/01/2019Race Receives $228k R&D Tax Incentive RefundDownload
25/01/2019Appendix 4C - quarterlyDownload
1  2  3  4  5  6  7  8  



Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2019 Race Oncology. Website By Multiplier